A Phase 1 trial shows a personalized DNA vaccine (GNOS-PV01) is safe and doubles survival rates for aggressive glioblastoma.
Summary: Researchers developed a personalized DNA cancer vaccine that has shown promising results in an early-stage clinical trial for glioblastoma.
The study demonstrates that the vaccine, GNOS-PV0… [+15409 chars]
The study demonstrates that the vaccine, GNOS-PV0… [+15409 chars]